Strategy for Secure and Sustainable Plasma Supply
There is a sustained increase in the global demand for plasma-derived medicinal products and this is likely to continue for the foreseeable future. The driver for the collection of plasma is currently mainly the immunoglobulin products which have a steady increase in global use. Currently, the raw material plasma supply to meet this need is predominantly from the US where 5% of the global population provides approximately 70% of the global plasma supply, and most of this plasma is collected by the commercial sector.
IPFA advocates a more diversified global plasma supply to minimize the risks of product shortage resulting from US plasma supply interruption or failure. The last years’ pandemic has shown a negative impact on US plasma collection which further underlines the vulnerability of the global situation. IPFA calls for National and Regional policies and strategies to promote increased plasma collection by the public sector who collect blood and plasma without financial gain for donors, and for a reduction of recovered plasma wastage worldwide by increased focus on plasma quality.
Please click here to access the paper “Plasma is a strategic resource” published in Transfusion 2016;56;3133-3137.